Lonza, Agennix Sign Deal for Production of Talactoferrin

12.04.2012 - Lonza and Agennix announced an agreement for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III...